Anaveon
Description: Anaveon develops selective IL-2 complexes to enhance T cell functions, offering effective cancer treatment as monotherapy or in combination.
Country: Switzerland
Based in: Bottmingen, Basel-Stadt
Founded: 2017
Funding Stage: Series A/B
Tags: ['Therapeutics']
ACCESS DIRECTORY
Details about how we process your information are available in our Privacy Policy.
